These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 29904848)
21. Catastrophizing attitude changes after onabotulinumtoxin A treatment in chronic migraine. Grazzi L; Grignani E; Sansone E; Raggi A; D'Amico D; Andrasik F Neurol Sci; 2019 May; 40(Suppl 1):201-202. PubMed ID: 30859415 [No Abstract] [Full Text] [Related]
22. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Cady RK; Schreiber CP; Porter JA; Blumenfeld AM; Farmer KU Headache; 2011 Jan; 51(1):21-32. PubMed ID: 21070228 [TBL] [Abstract][Full Text] [Related]
23. OnabotulinumtoxinA wear-off in chronic migraine, observational cohort study. Zidan A; Roe C; Burke D; Mejico L J Clin Neurosci; 2019 Nov; 69():237-240. PubMed ID: 31327585 [TBL] [Abstract][Full Text] [Related]
24. IncobotulinumtoxinA for Migraine: A Retrospective Case Series. Kazerooni R; Lim J; Ashley Blake P; Lessig S Clin Ther; 2015 Aug; 37(8):1860-4. PubMed ID: 26166734 [TBL] [Abstract][Full Text] [Related]
25. Chronic Cannabis Use and Treatment Failure of Onabotulinum Toxin A for Chronic Migraine. Chan TLH; Zhang N Can J Neurol Sci; 2019 Nov; 46(6):785-786. PubMed ID: 31469061 [No Abstract] [Full Text] [Related]
26. Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN Ion I; Renard D; Le Floch A; De Verdal M; Bouly S; Wacongne A; Lozza A; Castelnovo G Toxins (Basel); 2018 Jun; 10(6):. PubMed ID: 29857565 [TBL] [Abstract][Full Text] [Related]
27. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program. Lipton RB; Rosen NL; Ailani J; DeGryse RE; Gillard PJ; Varon SF Cephalalgia; 2016 Aug; 36(9):899-908. PubMed ID: 27288354 [TBL] [Abstract][Full Text] [Related]
29. What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group. Sacco S; Russo A; Geppetti P; Grazzi L; Negro A; Tassorelli C; Tedeschi G; Martelletti P Expert Rev Neurother; 2020 Dec; 20(12):1275-1286. PubMed ID: 32990477 [TBL] [Abstract][Full Text] [Related]
30. Decreased Pulmonary Function During Botulinum Toxin A Therapy for Chronic Migraines in a 17-Year-Old Female. Oliver JD; Boesch RP; Mack KJ Headache; 2018 Sep; 58(8):1259-1261. PubMed ID: 30033516 [No Abstract] [Full Text] [Related]
31. Onabotulinumtoxin A (BOTOX®) for ProphylaCTIC Treatment of Pediatric Migraine: A Retrospective Longitudinal Analysis. Shah S; Calderon MD; Wu W; Grant J; Rinehart J J Child Neurol; 2018 Aug; 33(9):580-586. PubMed ID: 29877131 [TBL] [Abstract][Full Text] [Related]
36. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. Silberstein SD; Dodick DW; Aurora SK; Diener HC; DeGryse RE; Lipton RB; Turkel CC J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):996-1001. PubMed ID: 25500317 [TBL] [Abstract][Full Text] [Related]
37. Chronic migraine: a therapeutic challenge for clinicians. Irimia P; Carmona-Abellán M; Martínez-Vila E Expert Opin Emerg Drugs; 2012 Dec; 17(4):445-7. PubMed ID: 22998764 [TBL] [Abstract][Full Text] [Related]
38. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. Negro A; Curto M; Lionetto L; Martelletti P J Headache Pain; 2015; 17():1. PubMed ID: 26792662 [TBL] [Abstract][Full Text] [Related]